Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covance Reports 2008 Results
“As previously announced, reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology
“As previously announced, reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology
Besides its lead drug, Ketotransdel (a topical nonsteroidal antiinflammatory drug currently in a Phase III trial for acute pain), the company is exploring potential co-development opportunities with corporate
GeoPharma receives $2.5 million in cash and notes and will maintain 40% ownership in the business under the terms of the agreement. GeoPharma hopes that the formation of
The company has reported net earnings of $1.53 billion for the fourth quarter of 2008, an increase of 28%, compared to $1.20 billion posted in the fourth quarter
James S. Kuo, Cordex’s chief executive officer commented, “We are pleased to have completed our corporate name change and selected a new ticker symbol. The Cordex name was
James Kelly, CEO of Stem Cell Innovations, said: “We have been working for several years to develop a more effective method for producing stem cells from germ cells.
Ethox produces proprietary medical devices and is engaged in contract manufacturing of disposables for many medical device companies. Ethox also provides microbiology, toxicology and sterilization services. In 2006,
Through the partnership, The Leukemia & Lymphoma Society (LLS) will provide $3.7 million to support Celator’s Phase IIb multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy
In the Phase II/III trial, patients are randomly assigned to one of two treatment arms. Those allocated to the defibrotide prophylaxis arm receive 25mg/kg/day in four divided doses
The pediatric vaccine is proposed to be indicated for active immunization against invasive pneumococcal disease and middle ear infections caused by Streptococcus pneumoniae in infants and children from